Table 3.
Summary of included studies of patients with LVAD using an ARNI.
| Study | Study Design | Follow-Up | Dose | Duration of ARNI | Types of Used LVAD | Device Strategy |
|---|---|---|---|---|---|---|
| Alishetti et al., 2020 [13] | Retrospective study | 3 or 6 months | 24–26 mg 49–51 mg 97–103 mg |
Three and six months | HM2, HM3, HVAD |
DT 16 (53.3%), BTT 13 (43.3%), BTR 1 (3.3%) |
| Sharma et al., 2020 [16] | Retrospective study | - | 49 of 51 mg orally twice daily. | One month | HM2, HVAD | - |
| Zorz et al., 2020 [17] | Case series | 6 months | - | six months | - | - |
| Randhawa et al., 2020 [9] | Case series | 16 (7–20) days | low (≤24–26 mg, six patients) moderate (49–51 mg, four patients) The highest dose (97–103 mg) in four patients. |
292 days (141–422) | Continuous flow-LVAD | DT (80%) Centrifugal (60%) |
| Goldberg et al., 2021 [8] | Case series | 3 months | 24/26 mg BID in 37%, up titrated to 49/51 mg BID in 44%, And reached 97/103 mg BID in 19%. |
2018 to 2020 | HM2 HM3 HVAD |
- |
| Schnettler et al., 2021 [15] | Observational study | - | - | 12 months | HVAD, HM3 | - |
| Rawley et al., 2023 [14] | Cohort study | 6 months | - | - | - | - |
Data are presented as the number (percentage), mean ± SD, and median (IQR). Abbreviations: ARNI, angiotensin receptor–neprilysin inhibitor; BID, twice a day; BTR, bridge to recovery; BTT, bridge to transplant; DT, destination therapy; HM2, Heartmate 2; HM3, Heartmate 3; HVAD, Heartware Ventricular Assist Device; IQR, interquartile range; LVAD, left ventricular assist device; SD, standard deviation.